Go Pro
→ Gold buyout deals have handed shareholders overnight gains up to 79 percent (From Golden Portfolio) (Ad)tc pixel Free SCPS Stock Alerts

Scopus BioPharma (SCPS) Competitors

Scopus BioPharma logo
$0.0001 0.00 (-75.00%)
As of 11:41 AM Eastern
Compare

SCPS vs. VINC, CLVR, NAVB, EVLO, and GNCA

Should you buy Scopus BioPharma stock or one of its competitors? Scopus BioPharma's main competitors and comparable companies include Vincerx Pharma (VINC), Clever Leaves (CLVR), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), and Genocea Biosciences (GNCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scopus BioPharma compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

44.0% of Vincerx Pharma shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Scopus BioPharma Neutral

Vincerx Pharma has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Scopus BioPharma N/A N/A N/A

Summary

Vincerx Pharma and Scopus BioPharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Scopus BioPharma Neutral

Clever Leaves has a beta of 3816.13, suggesting that its share price is 381,513% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market.

Scopus BioPharma has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Scopus BioPharma N/A N/A N/A

Summary

Clever Leaves beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Scopus BioPharma Neutral

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Scopus BioPharma has lower revenue, but higher earnings than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Scopus BioPharma N/A N/A N/A

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Evelo Biosciences?

Scopus BioPharma (NASDAQ:SCPS) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Scopus BioPharma has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Evelo Biosciences N/A N/A N/A

0.3% of Evelo Biosciences shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Evelo Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

Summary

Scopus BioPharma and Evelo Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

How does Scopus BioPharma compare to Genocea Biosciences?

Scopus BioPharma (NASDAQ:SCPS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Scopus BioPharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

0.6% of Genocea Biosciences shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Genocea Biosciences Neutral

Scopus BioPharma has higher earnings, but lower revenue than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Scopus BioPharma has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Summary

Scopus BioPharma beats Genocea Biosciences on 4 of the 7 factors compared between the two stocks.

Get Scopus BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCPS vs. The Competition

Export
MetricScopus BioPharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4K$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E RatioN/A775.15269.0625.28
Price / SalesN/A741.16592.9687.71
Price / CashN/A66.4570.4850.90
Price / BookN/A11.6012.916.24
Net Income-$11.61M$2.77B$3.45B$347.60M
7 Day PerformanceN/A0.17%1.12%1.07%
1 Month PerformanceN/A0.35%1.79%1.03%
1 Year PerformanceN/A161.52%67.69%20.77%

Scopus BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCPS
Scopus BioPharma
N/A$0.00
-75.0%		N/A+33.3%$4KN/AN/A9
VINC
Vincerx Pharma
N/A$0.01
flat		N/A-67.5%$66KN/AN/A60
CLVR
Clever Leaves
N/A$0.01
flat		N/A-50.0%$18K$17.42MN/A560
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
EVLO
Evelo Biosciences
N/AN/AN/AN/A$6KN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCPS) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel